| Company Name: |
ChemStrong Scientific Co.,Ltd
|
| Tel: |
0755-0755-66853366 13670046396 |
| Email: |
sales@chem-strong.com |
| Products Intro: |
Product Name:Mivacurium
CAS:133814-19-4
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
TOSUN PHARM
|
| Tel: |
020-61855200 13326451905 |
| Email: |
260366801@qq.com |
| Products Intro: |
Product Name:Mivacurium
CAS:133814-19-4
Purity:98%以上 Package:10mg;50mg;100mg等多种规格 Remarks:REF-M54001
|
Mivacurium manufacturers
- Mivacurium
-
- $100.00 / 1g
-
2023-04-11
- CAS:133814-19-4
- Min. Order: 10g
- Purity: 99%
- Supply Ability: 1000g
|
| | Mivacurium Basic information |
| Product Name: | Mivacurium | | Synonyms: | Mivacurium;(1R,1'R)-2,2'-[[(E)-1,8-Dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]isoquinolinium];(1R,1'R)-2,2'-[[(E)-1,8-Dioxo-4-octene-1,8-diyl]bis[oxy(3,1-propanediyl)]]bis[1-(3,4,5-trimethoxybenzyl)-2-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinium];Isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1R-(1R*(E(1'R*))))-;ILVYCEVXHALBSC-OTBYEXOQSA-N | | CAS: | 133814-19-4 | | MF: | C58H80N2O14+2 | | MW: | 1029.28 | | EINECS: | | | Product Categories: | API | | Mol File: | 133814-19-4.mol |  |
| | Mivacurium Chemical Properties |
| | Mivacurium Usage And Synthesis |
| Originator | Mivacron,GlaxoSmithKline S.p.A.,Italy | | Definition | ChEBI: Mivacurium is a member of isoquinolines. | | Manufacturing Process | To ()-5'-methoxylaudanosine (46.4 g) in methanol (240 mL) was added (-)-
dibenzoyltartaric acid monohydrate (45.2 g). The mixture was heated to
boiling, cooled at 5°C for 16 h and the (S)-(-)-5'-methoxylaudanosinium
dibenzoyltartrate salt (35.6 g, 80%) was filtered and discarded. The mother
liquors were made basic with concentrated aqueous NaOH and evaporated
under vacuum. The solid residue was partitioned between H2O and diethyl
ether. The ether phase was dried and evaporated to an oil (24.9 g). To the oil
in methanol (128 mL) was added (+)-dibenzoyltartaric acid monohydrate
(26.6 g). The mixture was heated to boiling and cooled at 5°C for 16 h.
Crystals were collected and recrystallized from methanol until a constant
specific rotation of [α]D20=+17.7° (1% EtOH) had been achieved. The yield of
(R)-(+)-5'-methoxylaudanosinium dibenzoyltartrate as white crystals was 29.4
g (66%). A portion of the salt (15.0 g) in methanol (200 mL) was made basic
with concentrated aqueous NaOH. The mixture was evaporated under vacuum
and the residue was partitioned between H2O and diethyl ether. The combined
ether layers were dried and evaporated under vacuum to yield 7.2 g (92%) of
(R)-(-)-5'-methoxylaudanosine as an oil.
(R)-(-)-5'-Methoxylaudanosine (7.2 g), 3-chloropropanol (3.5 g), sodium
iodide (5.6 g) and sodium carbonate (0.5 g) were refluxed in 2-butanone (125
mL) for 16 h. The white suspension was filtered hot and solvent removed from
the filtrate under vacuum. The residual gum was trituated with hot ethyl
acetate to remove excess 3-iodopropanol, dissolved in 200 mL methanol and
passed through a column packed with Dowex RTM.1-X8 ion exchange resin
(60 g chloride form). The eluant was stripped of solvent under vacuum to give
N-3-hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride (8.4 g) as an
amophous solid. The material was assayed by HPLC as a 2.3/1 mixture of the trans/cis diastereomers.
N-3-Hydroxypropyl-1-(R)-5'-methoxylaudanosinium chloride (2.3/1, trans/cis
by HPLC, 2.5 g) was dissolved in 60 mL 1,2-dichloroethane at about 70°C.
(E)-4-Octene-1,8-dioic acid chloride (0.5 g) (K. Sisido, K. Sei, and H. Nozaki,
J. Org. Chem., 1962, 27, 2681) was added and the mixture was stirred at
ambient temperature for 19 h. Solvent was removed under vacuum to give an
amorphous solid which was dissolved in chloroform (25 mL) and washed with
5% aqueous sodium chloride solution to remove unreacted quaternary salts.
The chloroform layer was dried and evaporated under vacuum to give an
amorphous solid. The acid ester impurities were substantially removed by
washing with hot 2-butanone. Residual solvent was evaporated under vacuum
and the resulting amorphous solid was dissolved in methanol, filtered and
lyophilized to give 1.9 g of (E)-(1R,1'R)-2,2'-[4-octenedioylbis
(oxytrimethylene)]bis[1,2,4,3-tetrahydro-6,7-dimethoxy-2-methyl-1-(3,4,5-
trimethoxybenzyl)isoquinolinium] dichloride, which was assayed by HPLC as
44.6% RS-RS (trans-trans) diester, 42.4% RR-RS (cis-trans) diester, 7.5% RRRR(cis-cis) diester, 4.0% RS (trans) acid ester and 1.5% RR (cis) (E)-
(1R,1'R)-2,2'-[4-Octenedioylbis(oxytrimethylene)]bis[1,2,3,4-tetrahydro-6,7-
dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium]dichloride acid
ester, [α]D20=-62.7° (1.9% in water). | | Therapeutic Function | Muscle relaxant | | Drug interactions | Potentially hazardous interactions with other drugs
Anaesthetics: enhanced muscle relaxant effect.
Anti-arrhythmics: procainamide enhances muscle
relaxant effect.
Antibacterials: effect enhanced by aminoglycosides,
clindamycin, polymyxins and piperacillin.
Antiepileptics: muscle relaxant effects antagonised by
carbamazepine; effects reduced by long-term use of
fosphenytoin and phenytoin but might be increased
by acute use.
Botulinum toxin: neuromuscular blockade enhanced,
(risk of toxicity). | | Metabolism | Mivacurium is a mixture of 3 stereoisomers, 2 of which
(cis-trans and trans-trans) are considered to account for
most of the neuromuscular blocking effect. All 3 isomers
are inactivated by plasma cholinesterase.
Renal and hepatic mechanisms are involved in their
elimination with excretion in urine and bile. |
| | Mivacurium Preparation Products And Raw materials |
|